chrispi ..."This transaction is transformational for Bioasis, bringing Phase 2 ready assets aligned with our focus in rare disease and orphan drug indications. EGF1-48 comes with a full IND package and clinical experience indicating that it is safe and well tolerated in humans."

With having RGFI-48 Phase 2 ready, how does this work in moving forward seeing that the Bioasis XB3 platform technology does not?

“The transfer of these assets to Bioasis will speed up the development of EGF therapeutics for the treatment of certain rare neurodegenerative disorders,”

So once this is all accomplished, does this mean that Bioasis will have a stand-alone drug and own it outright, passing on agreed-upon milestone payments etc.?  

Koo